Related Experiment Video
Updated: Aug 21, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.0K
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
Tingting Li1,2, Jiang Liu3, Weihua Wu3
1National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology, Beijing, China.
Frontiers in Cardiovascular Medicine
|November 17, 2022
Summary
Factor XI (FXI) inhibitors offer a safer approach to preventing and treating venous thromboembolism (VTE). These novel anticoagulants show efficacy comparable to existing treatments but with significantly reduced bleeding risk and improved patient compliance.
Area of Science:
- Hematology
- Pharmacology
- Thrombosis Research
Background:
- Venous thromboembolism (VTE) is a major cause of mortality and disability.
- Current anticoagulants have limitations, including recurrence, post-thrombotic syndrome, and bleeding risks.
- Safer anticoagulation strategies with better patient compliance are needed.
Purpose of the Study:
- To review the challenges in VTE therapy.
- To explore the role of Factor XI (FXI) in thrombosis.
- To summarize the latest FXI inhibitor strategies and clinical trial developments.
Main Methods:
- Review of epidemiological evidence and animal studies on FXI inhibitors.
- Analysis of recent clinical trial data comparing FXI inhibitors with enoxaparin and apixaban.
- Examination of FXI inhibitor pharmacokinetics and monitoring parameters.
Main Results:
- FXI inhibitors demonstrate efficacy in VTE prevention comparable to enoxaparin and apixaban.
- FXI inhibition significantly reduces bleeding incidence compared to current treatments.
- FXI inhibitors offer flexible dosing (daily/monthly) and simpler monitoring (aPTT).
Conclusions:
- Factor XI inhibition presents a promising and safer therapeutic strategy for VTE prevention and treatment.
- Ongoing clinical trials for FXI inhibitors show significant progress, with some in Phase III.
- FXI inhibitors represent a potential advancement in anticoagulant therapy.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
16
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
16
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
834
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
834
01:30Venous Thrombosis IV: Nursing Management
19
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
19
01:30Venous Thrombosis I: Introduction
23
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
23
01:16Clot Retraction and Fibrinolysis
6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K